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Mesovarian Leiomyomas in the Rat
by C. Gopinath* and W. A. Gibson*
Prolonged treatment with two chemically distinct 1-stimulants, Salbutamol and Terbutaline, resulted
in mesovarian leiomyomas in Sprague-Dawley rats. Development ofthese tumors induced by Salbutamol
wasprevented byconcurrent administration ofthe ,3-blockerPropranolol. Mesovarian leiomyomas induced
by Salbutomol did not show any regression or progression during a 44-week postdosing recovery period.
This report also gives the first recorded incidence of spontaneous mesovarian leiomyomas in the rat.
Introduction
Primary leiomyomas ofthe ovaries are uncommon in
man; one review recorded only five cases from a collec-
tion over a 36-year period (1). Smooth muscle cell tu-
mors of the ovaries are likewise rare in all species of
animals. We found no reported cases of spontaneous
mesovarian leiomyomas in rats in the published litera-
ture. In contrast to spontaneously occurring smooth
muscle cell tumors, mesovarian leiomyomas can be in-
duced in rats by prolonged administration of ,8-stimu-
lants.
This report describes the pathologic features and
compares the incidence of mesovarian leiomyomas in-
duced in female rats by two ,B-stimulants, Salbutamol
sulfate and Terbutaline sulfate, and shows the effects
on the incidence of Salbutamol-induced leiomyomas of
concurrent administration of the 13-blocker, Proprano-
lol. In addition, results from an extensive review of
ovaries from untreated rats are presented.
Materials and Methods
The test animals used were female Charles River CD
(Sprague-Dawley derived) rats, and the compounds
were administered orally in the diet. The study was
divided into two parts. Experimental design for Part I
is given in Table 1. Part II ofthe study consisted of200
female rats that were given Salbutamol at a dose level
of20 mg/kg/day for 80 weeks. Fifty rats were killed at
week 80, and the remaining survivors (98 rats) were
heldwithout treatmentfor apostdosing recoveryperiod
up to week 124. At this time all survivors were killed.
All animals were given a complete postmortem exam-
ination and tissues were fixed in 10% neutral buffered
formalin. Onlytheresultsofthemesovarianleiomyomas
are included in this report. In addition, a retrospective
review of ovary tissue diagnoses from 7748 untreated
rats in the Huntingdon Research Centre database was
*Huntingdon Research Centre, Huntingdon, Cambridgeshire,
PE18, 6ES, England.
Table 1. Experimental design (Part I).
Rats per
group, fe-
Group Treatmenta Dosage equivalentb male
1 Control 105
2 Salbutamol 2 mg/kg/day 55
(low dose)
3 Salbutamol 20 mg/kg/day 55
(high dose)
4 Terbutaline 6 mg/kg/day for 62 55
(low dose) weeks, then 12
mg/kg/dayc
5 Terbutaline 60 mg/kg/day for 62 55
(high dose) weeks, then 120
mg/kg/dayc
6 Salbutamol + 20 mg/kg/day plus 55
Propranalol 33 mg/kg/dayd
aRats treated for a total of 104 weeks.
bEstimated average amount ingested by each rat based on known
food consumption.
CThe dose ofTerbutaline was doubled from week 63 as itwas found
to give less than intended plasma concentrations inthe treatedrats
(2).
dThe dose of the Propranolol was that found to effectively abolish
the increase in heart rate caused by oral Salbutamol in the rat (2).
conducted to establish the spontaneous incidence ofme-
sovarian leiomyomas.
Results
Part I
A summary ofthe mesovarian smooth muscle lesions
observed in Part I ofthis studyisgiveninTable 2. Both
,B-stimulants, Salbutamol and Terbutaline (groups 3, 4,
and 5), produced mesovarian leiomyomas. There were
no rats with leiomyomas among the controls nor in the
group given Salbutamol plus Propranolol.
Eighteen of the rats with leiomyomas had grossly
detected lesions. Nine ofthese lesions were located on
the right side, six were bilateral, and three were seenGOPINATH AND GIBSON
Table 2. Incidence of mesovarian smooth muscle lesions.
No. ofrats with No. of rats with
macroscopic lesions in mesovarian No. ofrats with smooth
Group Treatment No. of rats examined mesovariuma leiomyomas muscle hyperplasia
1 Control 105 0 0 0
2 Salbutamol 55 0 0 2
2 mg/kg/day
3 Salbutamol 55 9 16 (23)b 2
20 mg/kg/day
4 Terbutaline 55 1 1 0
6/12 mg/kg/day
5 Terbutaline 55 8 7 (9) 2
60/120 mg/kg/day
6 Salbutamol + 55 0 0 0
Propranolol
20 mg + 33 mg/kg/day
aMacroscopic lesions included swelling, nodules, or masses.
bNumbers in parentheses are the total number ofleiomyomas observed.
on the left side. These tumors varied from 1 mm to 20 Forty-oneofthe200ratshadmacroscopicmesovarian
mmindiameter. Theearliestappearance ofaleiomyoma lesions present as swellings, nodules, or masses.
in this part of the study was at week 56 in a decedent Twenty-nine ofthese grossly detected lesions were on
rat from the group receiving Salbutamol at 20 mg/kg/ the right side, nine were bilateral, and three were on
day. the left side. The earliest appearance ofa leiomyoma in
thispart ofthe studywas atweek63. Thelesions varied
Part II from 2 mm in diameter to a 29 x 24 x 16 mmirregular
mass, the largest tumor. The lesions were located most
The incidence of leiomyomas seen in Part II of this frequently in the mesovarium extending into the hilar
study is given in chronological order in Table 3. There region of the ovary, dorsal to the ovary (Plate 1), and
were 52 intercurrent deaths during the dosing period sometimes freely in the mesovarian ligament, up to 12
(up to 80 weeks), and 50 more rats were killed at 80 mm away from the tip ofthe uterine horn. Macroscopic
weeks. Among these 102 rats, there were 17 rats with lesions appeared as fusiform swellings, spherical or
mesovarian leiomyomas. During the postdosing recov- ovoid nodules, or as irregular bosselated masses (Plate
eryperiod, there were another22 rats with mesovarian 2). Cut surfaces revealed dense whitish tissue with a
leiomyomas (among the remaining 98), including one faintly whorled pattern (Plate 3). Lesions were well-
which was killed at week 124. circumscribed, but had no distinct encapsulation.
Table 3. Incidence of leiomyomas in rats given Salbutamol for 80 weeks.
No. ofrats with No. of rats with
No. ofrats macroscopic mesovarian mesovarian No. of rats with smooth
Week ofdeath examined lesionsa leiomyomas muscle hyperplasia
Treatment period
0-59 11 0 -0 0
60-69 19 2 2(2)b 2
70-79 22 5 5(6) 3
Interim kill
80 50 12 10(11) 7
Recovery period
81-89 18 3 3(5) 1
90-99 26 6 7(7) 0
100-109 23 6 5(7) 0
110-119 17 5 6(7) 0
120-124 14 2 1(1) 0
aMacroscopic lesions included swelling, nodules, and masses.
bNumbers in parentheses indicate the total number ofleiomyomas observed.
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Histological Features
Histologically, leiomyomas appeared as well-circum-
scribed growths of smooth muscle fibers (Plates 4 and
5). The muscle fibers appeared as interlacing bundles,
with a crisscrossing pattern and were sometimes ar-
ranged in whorls (Plate 6). The muscle cells were long,
with abundant eosinophilic cytoplasm and cylindrical,
cigar-shaped nuclei with blunt ends (Plate 7). In some
of the microscopic fields, the nuclei appeared ovoid or
circular dependingonthe sectioningangle onthebundle
of muscle fibers. The tumor cells stained yellow with
van Gieson and red with Mason's trichrome. Sparse in-
terbundle collagen was also present in varying propor-
tions.
Irregular areas of smooth muscle tissue in excess of
the usual amount found in the mesovarium, the sus-
pensory ligaments, or in the ovarian hilus were diag-
nosed as smoothmuscle hyperplasia. Intheseinstances,
although the smoothmuscletissuewasfocallyinexcess,
the lesions lacked the characteristic patterns of inter-
lacing bundles or whorls seen in the tumors and ap-
peared as areas of irregular or parallel smooth muscle
fibers (Plate 8).
The review ofthe ovaries carried out to establish the
occurrence ofmesovarian leiomyomas amonguntreated
rats revealed four cases in 7748 rat ovaries examined.
These four cases had morphological features identical
to those described for the induced tumors described
previously.
Discussion
Leiomyomas recorded in this study arose from the
smooth muscle normally present in the mesovarium.
This muscle tissue extends into the ovarian hilus and
anteriorly into the ligaments. None of the tumors ex-
aminedshowedanyevidenceofmalignancy. The tumors
tended to occur more frequently on the right side than
the left, which was similar to a previous observation
(3).
Mesovarian leiomyomas were induced in rats by the
administration of two chemically distinct adrenergic
stimulants, Salbutamol and Terbutaline. Other ,-stim-
ulants like Soterenol hydrochloride and Mesuprine hy-
drochloride are known to induce these tumors in the rat
(3,4). Two other agonists, Zinterol and Reproterol,
were also reported to have induced leiomyomas in the
rat (2). A 12-month study in rats with high doses of
Mabuterol revealed 3 out of 56 rats with mesovarian
leiomyomas (5).
The induction of mesovarian leiomyomas in rats ap-
pears to be a general feature of P-stimulants. That the
induction of these benign tumors is a function of adre-
nergic stimulation was further evidenced by the fact
that the concurrent administration of the adrenergic
blocker, Propranolol, preventedtheirdevelopment. Me-
sovarian smooth muscle in the rat is known to contain
P2- adrenoceptors, and it is postulated that prolonged
and intense activation of,32-adrenoceptors that mediate
cellular relaxation might give rise to leiomyomas (6).
In Part II of this study, female rats treated with
Salbutamol 20 mg/kg/day for 80 weeks followed by a
postdosing recovery period of 44 weeks had a similar
incidence of mesovarian leiomyomas during the treat-
ment and recovery periods. Since these tumors were
still detected toward the end of the recovery period,
and there were no appreciable differences in the size of
the masses detected, it can be concluded that these
lesions were neither reversible nor progressive.
Beta-stimulants are known to induce mesovarian
leiomyomas in different strains ofrats such as Sprague-
Dawley derived (Charles River CD strain), pigmented
Long Evans, and Wistar derived (Jcl) rats (2,3,5). 13-
stimulants are not known to produce mesovarian leio-
myomas in mice or other species oflaboratory animals.
This class of pharmacological compounds has been ex-
tensively used formore than 15 years in man, and there
isno evidence ofanyincreased incidence ofsmoothmus-
cletumors amongusers ofthesedrugs(7). Itisapparent
from this report that these tumors in the rat are not
unique to 1-stimulants but do occur spontaneously, al-
beit exceptionally rarely.
The authors wish to thank D. Poynter, Glaxo Research Ltd., Eng-
land, for permission to use results of this experiment carried out at
Huntingdon Research Centre. We are grateful to A. Galloway for
typing this manuscript and to M. Cannon for the photographic work.
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PLATE 1. Mesovarian leiomyoma sitluated dorsal to the right ovary. Bar = 2 mm.
PLATE 2. Alargemesovarianleiomyoma; notethemultinodularbos-
selated appearance. Bar = 5 mm.
PLATE 3. Mesovarian leiomyoma. Cut surface revealing faint whorled
pattern. Bar = 5 mm.
110MESOVARIAN LEIOMYOMAS
PLATE 4. Mesovarian leiomyoma situated at ovarian hilus. H & E. Bar = 1 mm.
PLATE 5. Mesovarian leiomyoma on the right mesovarian ligament. H & E. Bar = 1 mm.
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PLATE 6. Mesovarian leiomyoma showing criss-crossing pattern of muscle bundles. H & E. Bar = 100 ,m.
PLATE 7. Mesovarian leiomyoma showing elongated cells with cigar-shaped nuclei. H & E. Bar = 20 ,um.
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PLATE 8. An area of mesovarian smooth muscle hyperplasia. H & E. Bar = 40 ,um.
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